Clinical Trial Finder

Inclusion Criteria:

• - DNA damage response (DDR) mutations documented in the past medical record or confirmed during the screening period.

• - Measurable disease defined by RECIST 1.1.

• - Life expectancy ≥ 3 months.

• - Subject must be capable of oral administration of study medication.

Exclusion Criteria:

• - Subject has had a cytotoxic chemotherapy, immunotherapy, radiotherapy or other targeted therapies within 4 weeks.

• - Surgical procedure performed within 7 days prior to first scheduled dose of ATRN-119.

• - Concomitant treatment with strong inhibitors or inducers of CYP3A4 and CYP2D6.

• - Known human immunodeficiency virus infection (HIV).

• - Subjects with active viral or bacterial infections and/or receiving systemic antibiotics or anti-viral medications.

• - Current or past diagnosis of leukemia within the past 5 years.

• - Prior radiotherapy at the target lesion unless there is evidence of disease progression.

• - Known CNS metastases or clinical evidence of CNS involvement that is not stable for previous 1 month by radiology documentation (magnetic resonance imaging [MRI] brain).

• - History of non-malignant gastronintestinal (GI) bleeding, gastric stress ulcerations, or peptic ulcer disease within the past 3-months.

• - Patient has uncontrolled hypertension at time of enrollment.

• - Complete left bundle branch block (LBBB), bifascicular block (right bundle branch block [RBBB] with either left anterior hemiblock or left posterior hemiblock).

• - Any clinically significant ST segment and/or T-wave abnormalities.

• - Myocardial infarction or unstable angina pectoris within 6 months prior to starting study medication.

Arms

Experimental: 50mg ATRN-119

Once daily oral administration.

Experimental: 100mg ATRN-119

Once daily oral administration.

Experimental: 200mg ATRN-119

Once daily oral administration.

Experimental: 350mg ATRN-119

Once daily oral administration.

Experimental: 550mg ATRN-119

Once daily oral administration.

Experimental: 800mg ATRN-119

Once daily oral administration.

Interventions

Drug: - ATRN-119

ATRN-119 is a capsule formulation that will be supplied as 50 mg and 200 mg hydroxymethyl cellulose (HPMC) capsules packed in sealed plastic bottles (n=30) and dispensed by the site pharmacist in combinations to provide the appropriate dose.